An activist shareholder group aptly named Hope for MannKind has gone public with a campaign to reform the marketing strategy for Afrezza, an inhalable form of insulin and the only commercial product of MannKind Corp. in Westlake Village. Dr. Bill McCullough, MannKind shareholder and chief executive at Vdex Diabetes, founded the group. Vdex operates a chain of clinics in California and New Mexico to help diabetic patients maintain low blood glucose levels. The clinics feature Afrezza as one of their primary drugs to achieve their goal. Read the full story in the Sept. 2 issue of the San Fernando Valley Business Journal.
